Clinical Trial of GeoVax’s AIDS Vaccine Moves Forward
As President Obama prepares to release his U.S. AIDS strategy, at least one pharmaceutical company is readying a crucial clinical trial of its vaccine against HIV/AIDS.
feature2
Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
Special Session On Health Savings Accounts at OneMedForum New York 2010
Health Savings Accounts have been a central part of healthcare reform plans under both the Bush and Obama administrations, touted as a way for consumers to save on medical costs. But how will they be affected by the healthcare reform bill passed in March?
Making Reimbursement Work In a Post-Healthcare Reform World
The passage of healthcare reform in March brought a wave of reimbursement-related headaches to the life science industry.
[OneMedForum] MacuCLEAR Sees Unmet Need for Vision-Loss Treatment
With the large Baby Boomer population reaching its senior years, the incidence of age-related vision loss in the U.S. is expected to increase.
The Value of Intellectual Property
Even before a drug or medical device reaches blockbuster status, protecting intellectual property should still be a priority.
How to Get Noticed by Big Pharma
Less than 15 percent of unsolicited inquiries to Big Pharma actually get reviewed.
How can a pharmaceutical startup grab the attention of Big Pharma?
Father’s Day Draws Attention to Prostate Cancer
Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Leading New York Research Institutions to Showcase at OneMedForum
OneMedPlace announced that the leading Universities and Hospitals in the New York area will showcase their most promising medical technologies June 30th at the OneMedForum NY 2010 in Midtown Manhattan.
Workshop to Show Companies How to Navigate FDA Approval Process
Tougher FDA requirements for the drug approval process, implemented in the wake of the Vioxx disaster, have added confusion–and, according to drug companies, delays–into the mix for many pharmaceutical manufacturers. With the new requirements, drug developers may be unsure of what to file and how to file.